MedTrace Logo

Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients

NCT00875771 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2017-08-01

No results posted yet for this study

Summary

The purpose of this study is to determine efficacy and safety of the biweekly scheme with Capecitabine and Irinotecan, plus bevacizumab in patients with metastatic colorectal cancer.

Conditions

Interventions

DRUG

Capecitabine+Irinotecan+Bevacizumab

* Capecitabine: 1000 mg/m2, bid, oral, days 2-8. Every 2 weeks * Irinotecan: 175 mg/m2, iv infusion 90 minutes, day 1, every 2 weeks * Bevacizumab: 5 mg/kg day 1, every 2 Weeks Treatment will be given until disease progression or unacceptable toxicity.

Sponsors & Collaborators

  • Hoffmann-La Roche

    collaborator INDUSTRY

  • Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

    lead OTHER

Principal Investigators

  • Pilar García Alfonso, MD · Hospital Gregorio Marañón. Madrid. Spain

  • Enrique Aranda, MD; phD · Hospital Reina Sofía. Cordoba. Madrid

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00875771 on ClinicalTrials.gov